<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "http://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
      <PMID Version="1">31400583</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>11</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>11</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0461</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>142</Volume>
            <PubDate>
              <Year>2019</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Critical reviews in oncology/hematology</Title>
          <ISOAbbreviation>Crit. Rev. Oncol. Hematol.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer.</ArticleTitle>
        <Pagination>
          <MedlinePgn>119-129</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">S1040-8428(19)30140-4</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.critrevonc.2019.06.014</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The role of hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin in addition to cytoreductive surgery (CRS) has recently been questioned in peritoneal metastases of colorectal cancer. Whether this applies to all published CRS/HIPEC regimens is unclear.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">A systematic literature search identified 46 studies on CRS/HIPEC using either oxaliplatin of mitomycin C with at least one oncological outcome parameter RESULTS: Oxaliplatin and mitomycin C studies were comparable regarding extent of disease, but differed substantially regarding synchronous versus metachronous presentation, application of neo-adjuvant systemic chemotherapy, duration of HIPEC, and completeness of cytoreduction for at least one of the oncological endpoints. Severe postoperative complication rate seemed significantly higher after oxaliplatin-based CRS/HIPEC.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Published cohorts on oxaliplatin-based CRS/HIPEC differed essentially from MMC-based procedures, especially considering the application of oxaliplatin-containing neo-adjuvant systemic therapy and shorter exposure time to intraperitoneal chemotherapy in oxaliplatin studies. No meaningful comparison could be made regarding DFS and OS.</AbstractText>
          <CopyrightInformation>Copyright © 2019 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wisselink</LastName>
            <ForeName>Daan D</ForeName>
            <Initials>DD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, the Netherlands. Electronic address: d.d.wisselink@amc.uva.nl.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Braakhuis</LastName>
            <ForeName>Linde L F</ForeName>
            <Initials>LLF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, the Netherlands. Electronic address: l.l.braakhuis@amc.uva.nl.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gallo</LastName>
            <ForeName>Gaetano</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical and Surgical Sciences, Università Magna Graecia di Catanzaro, Viale Europa, 88100 Catanzaro, CZ, Italy. Electronic address: gaetanogallo1988@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van Grevenstein</LastName>
            <ForeName>Wilhelmina M U</ForeName>
            <Initials>WMU</Initials>
            <AffiliationInfo>
              <Affiliation>Department of surgery, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands. Electronic address: W.M.U.vanGrevenstein@umcutrecht.nl.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van Dieren</LastName>
            <ForeName>Susan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Research Unit, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, the Netherlands. Electronic address: s.vandieren@amc.uva.nl.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kok</LastName>
            <ForeName>Niels F M</ForeName>
            <Initials>NFM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of surgery, Antoni van Leeuwenhoek hospital, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands. Electronic address: n.kok@nki.nl.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Reuver</LastName>
            <ForeName>Philip R</ForeName>
            <Initials>PR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of surgery, Radboud University Medical Centre, Geert Grooteplein-Zuid 22, 6525 GA Nijmegen, the Netherlands. Electronic address: Philip.deReuver@radboudumc.nl.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tanis</LastName>
            <ForeName>Pieter J</ForeName>
            <Initials>PJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, the Netherlands. Electronic address: p.j.tanis@amsterdamumc.nl.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Hingh</LastName>
            <ForeName>Ignace H J T</ForeName>
            <Initials>IHJT</Initials>
            <AffiliationInfo>
              <Affiliation>Department of surgery, Catharina hospital, Michelangelolaan 2, 5623 EJ Eindhoven, the Netherlands. Electronic address: Ignace.d.hingh@catharinaziekenhuis.nl.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>07</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Crit Rev Oncol Hematol</MedlineTA>
        <NlmUniqueID>8916049</NlmUniqueID>
        <ISSNLinking>1040-8428</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>04ZR38536J</RegistryNumber>
          <NameOfSubstance UI="D000077150">Oxaliplatin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>50SG953SK6</RegistryNumber>
          <NameOfSubstance UI="D016685">Mitomycin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065426" MajorTopicYN="N">Cytoreduction Surgical Procedures</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006979" MajorTopicYN="Y">Hyperthermia, Induced</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016685" MajorTopicYN="N">Mitomycin</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077150" MajorTopicYN="N">Oxaliplatin</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010534" MajorTopicYN="N">Peritoneal Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
          <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Colorectal cancer</Keyword>
        <Keyword MajorTopicYN="N">Cytoreductive surgery</Keyword>
        <Keyword MajorTopicYN="N">HIPEC</Keyword>
        <Keyword MajorTopicYN="N">Mitomycin C</Keyword>
        <Keyword MajorTopicYN="N">Morbidity</Keyword>
        <Keyword MajorTopicYN="N">Oxaliplatin</Keyword>
        <Keyword MajorTopicYN="N">Peritoneal metastases</Keyword>
        <Keyword MajorTopicYN="N">Survival</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>05</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>06</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31400583</ArticleId>
        <ArticleId IdType="pii">S1040-8428(19)30140-4</ArticleId>
        <ArticleId IdType="doi">10.1016/j.critrevonc.2019.06.014</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
